Velimir Šimičević
University of Zagreb
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Velimir Šimičević.
Life Sciences | 1993
Predrag Sikiric; Sven Seiwerth; Zeljko Grabarevic; Rudolf Rucman; Marijan Petek; Ivo Rotkvic; Branko Turkovic; Vjekoslav Jagić; Boris Mildner; Marko Duvnjak; Zarko Danilović; Marko Kolega; Ahmet Sallmani; Sanja Dacic; Milan Dodig; Nada Lang; Jadranka Separovic; V. Corić; Velimir Šimičević; Krešimir Bulić; Marija Veljača; Nevena Skroza; Marko Banić; Tomislav Brkić; Gojko Buljat; Stjepan Mise; Drazen Lucinger; Miljenko Bura
The hepatoprotective effects of a newly synthesized 15 amino acid fragment code named BPC 157 was evaluated in comparison with the reference standards (bromocriptine, amantadine and somatostatin) in various experimental models of liver injury in rats: 24 h-bile duct+hepatic artery ligation 48 h-restraint stress and CCl4 administration. BPC 157 administered either intragastrically or intraperitoneally, significantly prevented the development of liver necrosis or fatty changes in rats subjected to 24 h bile duct + hepatic artery ligation, 48 h-restraint stress, CCl4 treatment (1 ml/kg i.p., sacrifice 48 h thereafter). The other reference drugs had either little or no protective actions in these models. Noteworthy, the laboratory test results for bilirubin, SGOT, SGPT fully correlated with the macro/microscopical findings. Thus, on the basis of consistent protective effect of BPC 157, possible clinical application in liver diseases is now warranted.
Journal of Physiology-paris | 1997
P Sikiric; Sven Seiwerth; Zeljko Grabarevic; Rudolf Rucman; Marijan Petek; Vjekoslav Jagić; Branko Turkovic; Ivo Rotkvic; Stjepan Mise; Ivan Zoricic; Paško Konjevoda; Darko Perovic; Velimir Šimičević; Jadranka Separovic; Miroslav Hanzevacki; Danica Ljubanović; Branka Artuković; Mirna Bratulić; Marina Tišljar; B Rekic; Miroslav Gjurasin; Pavle Miklic; Gojko Buljat
Besides a superior protection of the pentadecapeptide BPC 157 (an essential fragment of an organoprotective gastric juice peptide BPC) against different gastrointestinal and liver lesions, an acute anti-inflammatory and analgetic activity was also noted. Consequently, its effect on chronic inflammation lesions, such as adjuvant arthritis, and non-steroidal anti-inflammatory agents (NSAIAs)-induced gastrointestinal lesions was simultaneously studied in rats. In gastrointestinal lesions (indomethacin (30 mg/kg s.c.), aspirin (400 mg/kg i.g.) and diclofenac (125 mg/kg i.p.) studies, BPC 157 (10 micrograms or 10 ng/kg i.p.) was regularly given simultaneously and/or 1 h prior to drug application (indomethacin). In the adjuvant arthritis (tail-application of 0.2 mL of Freunds adjuvant) studies (14 days, 30 days, 1 year) BPC 157 (10 micrograms or 10 ng/kg i.p.), it was given as a single application (at 1 h either before or following the application of Freunds adjuvant) or in a once daily regimen (0-14th day, 14-30th day, 14th day-1 year). Given with the investigated NSAIAs, BPC 157 consistently reduced the otherwise prominent lesions in the stomach of the control rats, as well as the lesions in the small intestine in the indomethacin groups. In the adjuvant arthritis studies, the lesions development seems to be considerably reduced after single pentadecapeptide medication, and even more attenuated in rats daily treated with BPC 157. As a therapy of already established adjuvant arthritis, its salutary effect consistently appeared already after 2 weeks of medication and it could be clearly seen also after 1 year of application. Taking together all these results, the data likely point to a special anti-inflammatory and mucosal integrity protective effect.
Inflammopharmacology | 1993
P Sikiric; K. Gyires; Sven Seiwerth; Z. GrabarevlĆ; Rudolf Rucman; Marijan Petek; Ivo Rotkvic; Branko Turkovic; I. UdoviČĆ; Vjekoslav Jagić; Boris Mildner; Marko Duvnjak; Zarko Danilović; Marko Kolega; Ahmet Sallmani; Sanja Djačić; Miroslav Hanzevacki; Nada Lang; Velimir Šimičević; Marija Veljača; V. Orihovać; Marko Banić; Tomislav Brkić; Gojko Buljat; Darko Perovic; Stjepan Mise; A. MarovlĆ; Jadranka Separovic; V. Corić; Krešimir Bulić
The anti-nociceptive effects of a newly synthesized pentadecapeptide coded BPC 157 (an essential fragment of new organoprotective gastric juice peptide BPC) was evaluated in comparison with aspirin and morphine reference standards, in various experimental models of indirect/direct nociception and neurotoxicity: writhing (acetic acid/magnesium sulphate), tail pinching, hot-plate, and capsaicin application. BPC 157 administered either in the ng or μg per kg range, intraperitoneally, significantly reduced the reactions in the writhing (inflammatory and non-inflammatory, prostaglandin-dependent and independent) and tail pinching tests. In the hot-plate test, unlike morphine, BPC 157 had no effect on normal animals. However, when given to capsaicin treated rats, BPC 157 strongly reduced capsaicin-allodynia, either given as pretreatment or once daily for 14 days after the capsaicin injection. This reduction in capsaicin’s effect could not be obtained when BPC 157 was applied in the presence of established capsaicin-somatosensory neuron degeneration (application only on the 14th day after capsaicin), so it is possible that the effects of BPC 157 could be related specifically to the integrity of capsaicin-sensitive somatosensory neurons and their protection (e.g. primary afferent neurons having small-diameter somata and unmyelinated (C-) or thinly myelinated (A6-) fibres).
Biometals | 1997
Branko Troskot; Velimir Šimičević; Milan Dodig; Ivo Rotkvic; Davor Ivanković; Marko Duvnjak
Exogenously administered zinc compounds have been shown to possess antiulcer activity in the development of gastric lesions. The aim of this study was to investigate the effects of zinc sulphate pretreatment of rats on cysteamine-induced duodenal ulcers and to correlate them with changes in zinc serum and tissue levels. Atomic absorption spectrophotometry was used to determine zinc serum and tissue concentrations in all animal groups. Cysteamine produced marked duodenal ulceration in control animals 24 h after application, with an increase in endogenous zinc tissue concentrations and a marked decrease in serum concentrations. Zinc sulphate (20, 40 or 80 mg kg-1) applied per os one hour prior to cysteamine application inhibited the development of duodenal lesions in a dose-related manner. The application of zinc sulphate in a single intraperitoneal (i.p.) application (80 mg kg-1) did not, however, prevent the formation of duodenal lesions. In order to assess zinc absorption from the gastrointestinal tract, one group of rats received a single oral dose of zinc sulphate (80 mg kg) without cysteamine application. The observations of this study seem to indicate that zinc plays an important cytoprotective role in duodenal ulcer disease.
Biometals | 1996
Branko Troskot; Velimir Šimičević; Milan Dodig; Ivo Rotkvic; Davor Ivanković; Marko Duvnjak
Exogenously administered zinc compounds have been shown to possess anti-ulcer activity against a wide variety of ulcerogenic agents, both in laboratory animal models and in human peptic ulcer disease. However, a strong possibility exists that endogenous zinc may also play an important role during noxious events by various mechanisms. Therefore, the aim of this study was to focus on the changes of endogenous zinc serum and tissue concentrations in cysteamine-induced duodenal lesions. We used atomic absorption spectropho-tometry to determine the tissue and serum concentrations of zinc in normal (control) rats and those with cysteamine-induced duodenal ulcers. The results obtained in this study indicated that the onset, development and spontaneous healing of ulcer lesions were associated with certain shifts in zinc serum and tissue concentrations. Prior to ulcer formation, a significant increase was noted in serum zinc values. With the onset of duodenal lesions, zinc serum concentrations significantly decreased, while there was a significant increase in duodenal tissue concentrations when compared to healthy control animals. Zinc tissue concentrations decreased and returned to starting values by the end of the first week of spontaneous healing. This decrease in zinc tissue concentration corresponded to the healing rate of the duodenal ulcers. Serum zinc concentrations also returned to starting values within the first week period. These observations indicate and confirm that zinc could play an important role in duodenal ulcer disease and represent a natural defense system in the body.
Journal of Physiology-paris | 1993
V. Corić; Josip Čulig; Ivan Zoricic; Ahmet Sallmani; S. Mikulandra; S. Bogdan; Velimir Šimičević; Krešimir Bulić; Marko Kolega; K. Derniković; S. Djačić; I. Karakas; Sven Seiwerth; Zeljko Grabarevic; P Sikiric; Marijan Petek; Rudolf Rucman; I. Jelić
The main purpose of this study was to further investigate the effects of vagotomy on gastric lesion development. In contrast to the usual subdiaphragmal vagotomy, a different vagotomy at the level of the trigonum caroticum was used both alone and in combination with pylorus ligation (done immediately after vagal transection). The animals were killed 15 min, 30 min, 1 h and 6 h following vagotomy. No damaging effects of sham-vagotomy, or obvious negative effects of cervical vagotomy were noted. Prominent lesions appeared after 1 h in rats subjected to cervical vagotomy and significantly increased lesions in the early period of pylorus ligation were noted. No further aggravation in pylorus ligated rats (even an apparent amelioration at 1-h interval) and no lesions in rats with cervical vagotomy in the latter period could be explained in terms of a lack of reactivity due to exhaustion preceding fatal outcome. Consistent with this, the rats subjected to cervical vagotomy died shortly after the 6-h period.
Journal of Physiology-paris | 1993
P Sikiric; Marijan Petek; Rudolf Rucman; Sven Seiwerth; Zeljko Grabarevic; Ivo Rotkvic; Branko Turkovic; Vjekoslav Jagić; Boris Mildner; Marko Duvnjak; Nada Lang; Zarko Danilović; A. Cviko; Marko Kolega; Ahmet Sallmani; Sanja Djačić; Miljenko Bura; Tomislav Brkić; Marko Banić; Milan Dodig; V. Corić; Velimir Šimičević; Marija Veljača; D. Erceg; D. Ježek; L.J. Simunić-Banek; N. Skroza; Krešimir Bulić; Gojko Buljat; M. Hanževački
Acta medica Croatica : c̆asopis Hravatske akademije medicinskih znanosti | 1999
Marko Duvnjak; Supanc; Velimir Šimičević; Hrabar D; Branko Troskot; Lea Smirčić-Duvnjak; Bekavac-Beslin M
Pharmaca : hrvatski časopis za farmakoterapiju | 2002
Marko Duvnjak; Lucija Virović; Vladimir Supanc; Branko Troskot; Zoran Antić; Igor Kovačević; Davor Hrabar; Neven Ljubičić; Velimir Šimičević
Acta Clinica Croatica | 2001
Marko Duvnjak; Vladimir Supanc; Velimir Šimičević; Davor Hrabar; Branko Troskot; Lea Smirčić-Duvnjak; Rajko Ostojić; Senka Radošević